EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Replacement of the Mouse LD50 Assay for Determination of the Potency of AbobotulinumtoxinA with a Cell-Based Method in Both Powder and Liquid Formulations

Elena Fonfria iD, Elizabeth Marks, Lisa-Marie Foulkes, Rebecca Schofield, Daniel Higazi, Sam Coward, Alistair Kippen

Toxins · 2023

DOI: 10.3390/toxins15050314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2023. Verfasst von Elena Fonfria und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ipsen Bioinnovation, Abingdon OX14 4RY, UK. Hauptthemen laut MEDLINE: Neurotoxins, Botulinum Toxins, Type A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ipsen Biopharm Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Botulinum neurotoxins (BoNTs) are important therapeutic agents. The in vivo median lethal dose (LD50) assay has been commonly used to measure the potency of BoNT commercial preparations. As an alternative, we developed cell-based assays for abobotulinumtoxinA in both powder (Dysport®, Azzalure®) and liquid (Alluzience®) formulations using the in vitro BoCell® system. The assays demonstrated linearity over 50–130% of the expected relative potency, with a correlation coefficient of 0.98. Mean recoveries of 90–108% of the stated potency were observed over this range. The coefficients of variation for powder and liquid formulations, respectively, were 3.6% and 4.0% for repeatability and 8.3% and 5.0% for intermediate precision. A statistically powered comparability assessment of the BoCell® and LD50 assays was performed. Equivalence was demonstrated between the assays for the liquid formulation at release and end of shelf life using a paired equivalence test with predefined equivalence margins. For the powder formulation, the assays were also shown to be equivalent for release samples and when determining loss of potency following thermal degradation. The BoCell® assay was approved for establishing the potency of abobotulinumtoxinA for both powder and liquid formulations in Europe and for the powder formulation only in the USA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurotoxinsBotulinum Toxins, Type AAnimalsMicePowdersLethal Dose 50

Stichwörter der Autor:innen

CBALD50botulinumpotencyreplacementtoxin

Substanzen

abobotulinumtoxinANeurotoxinsPowdersBotulinum Toxins, Type A

Autor:innen und Institutionen

  • Ipsen Bioinnovation, Abingdon OX14 4RY, UK.
  • Ipsen Biopharm Ltd., Wrexham LL13 9UF, UK.

ORCID-Profile: Elena Fonfria

Förderung

  • Ipsen Biopharm Ltd

Zitieren

APA

Fonfria, E., Marks, E., Foulkes, L. M., Schofield, R., Higazi, D., Coward, S., & Kippen, A. (2023). Replacement of the Mouse LD50 Assay for Determination of the Potency of AbobotulinumtoxinA with a Cell-Based Method in Both Powder and Liquid Formulations. Toxins. https://doi.org/10.3390/toxins15050314

Vancouver

Fonfria E, Marks E, Foulkes LM, Schofield R, Higazi D, Coward S, et al. Replacement of the Mouse LD50 Assay for Determination of the Potency of AbobotulinumtoxinA with a Cell-Based Method in Both Powder and Liquid Formulations. Toxins. 2023. doi:10.3390/toxins15050314

BibTeX
@article{Fonfria2023,
  author = {Fonfria, Elena and Marks, Elizabeth and Foulkes, Lisa-Marie and Schofield, Rebecca and Higazi, Daniel and Coward, Sam and Kippen, Alistair},
  title = {Replacement of the Mouse LD50 Assay for Determination of the Potency of AbobotulinumtoxinA with a Cell-Based Method in Both Powder and Liquid Formulations},
  journal = {Toxins},
  year = {2023},
  doi = {10.3390/toxins15050314}
}
Kostenlos starten →